| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary targets of 4-feruloylquinic acid are reactive oxygen species (ROS) and inflammatory mediators. As a phenolic compound, it acts as an antioxidant by scavenging free radicals and chelating metal ions. It may also modulate inflammatory signaling pathways by inhibiting the production of pro-inflammatory cytokines and the activation of transcription factors such as NF-κB. The compound's effects on metabolic pathways, including glucose and lipid metabolism, have also been reported.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that 4-feruloylquinic acid exhibits significant antioxidant activity by scavenging DPPH and ABTS free radicals. The compound also shows anti-inflammatory activity by reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6 in stimulated immune cells. It inhibits the activation of NF-κB and MAPK signaling pathways, which are involved in inflammatory responses. Additionally, the compound shows protective effects against oxidative stress-induced cell damage.
|
| ln Vivo |
In vivo studies in animal models have shown that 4-feruloylquinic acid exhibits antioxidant, anti-inflammatory, and metabolic benefits. In models of inflammation, the compound reduces the levels of inflammatory markers and tissue damage. In metabolic disease models, it improves glucose tolerance and lipid profiles. The compound's protective effects on the cardiovascular system have also been reported, including reductions in blood pressure and improvements in endothelial function.
|
| Enzyme Assay |
Non-cellular assays for 4-feruloylquinic acid typically involve measuring its antioxidant activity using DPPH, ABTS, or FRAP assays. The compound's ability to scavenge free radicals is quantified by measuring the reduction in absorbance at specific wavelengths. Metal chelating activity may also be assessed. These cell-free systems allow for precise characterization of the compound's antioxidant properties without cellular interference.
|
| Cell Assay |
Cellular assays for 4-feruloylquinic acid are conducted using various cell lines to assess its biological activities. Antioxidant activity is evaluated by measuring the compound's ability to reduce intracellular ROS levels in cells exposed to oxidative stress. Anti-inflammatory activity is assessed by measuring cytokine production and NF-κB activation in stimulated immune cells. Cell viability is measured using MTT assays to assess cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments for 4-feruloylquinic acid typically use rodent models of inflammation, metabolic disease, or oxidative stress. The compound is administered orally or intraperitoneally, and its effects on inflammatory markers, oxidative stress parameters, and metabolic endpoints are assessed. Tissue samples are collected for histopathological examination and biochemical analysis. These studies provide insights into the compound's potential health benefits.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-feruloylquinic acid have been characterized in some studies. As a polar compound with multiple hydroxyl groups, it may have limited oral bioavailability due to poor membrane permeability and extensive metabolism. The compound is absorbed in the gastrointestinal tract and undergoes metabolism to ferulic acid and other metabolites. Its half-life and tissue distribution depend on the route of administration and the specific experimental conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4-feruloylquinic acid indicate that it has a favorable safety profile, consistent with its presence in commonly consumed foods such as coffee. No significant toxicity has been reported at typical dietary intake levels. High doses may cause gastrointestinal discomfort due to its phenolic nature. The compound is generally recognized as safe for consumption as a component of food.
|
| References | |
| Additional Infomation |
4-O-feruloylquinic acid is an organic molecular entity. It has been reported that Coptis chinensis and Robusta coffee contain 4-O-feruloyl-D-quinic acid, and relevant data are available for reference.
Other information includes the compound's presence in coffee and other plant sources as a major chlorogenic acid derivative. It contributes to the antioxidant activity and potential health benefits of coffee consumption. The compound has been studied for its potential protective effects against cardiovascular disease, diabetes, and other chronic conditions. It is used as a reference standard in analytical chemistry for the quantification of chlorogenic acids in food and biological samples. |
| Molecular Formula |
C17H20O9
|
|---|---|
| Molecular Weight |
368.34
|
| Exact Mass |
368.11
|
| CAS # |
2613-86-7
|
| PubChem CID |
10177048
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
656.1±55.0 °C at 760 mmHg
|
| Flash Point |
238.9±25.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.646
|
| LogP |
-0.76
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
534
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=C(C=CC(=C1)/C=C/C(=O)OC2[C@@H](CC(C[C@H]2O)(C(=O)O)O)O)O
|
| InChi Key |
VTMFDSJJVNQXLT-XQCMRRNBSA-N
|
| InChi Code |
InChI=1S/C17H20O9/c1-25-13-6-9(2-4-10(13)18)3-5-14(21)26-15-11(19)7-17(24,16(22)23)8-12(15)20/h2-6,11-12,15,18-20,24H,7-8H2,1H3,(H,22,23)/b5-3+/t11-,12-,15?,17?/m1/s1
|
| Chemical Name |
(3R,5R)-1,3,5-trihydroxy-4-[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxycyclohexane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (135.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (3.39 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (3.39 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 1.25 mg/mL (3.39 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7149 mL | 13.5744 mL | 27.1488 mL | |
| 5 mM | 0.5430 mL | 2.7149 mL | 5.4298 mL | |
| 10 mM | 0.2715 mL | 1.3574 mL | 2.7149 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
